AI Firms Pivoting to Biomedical Research: Great for Humanity, Bearish for Business
iskander · x · 2026-07-30
Commentators point out that AI companies turning to biomedical research is awesome for humanity, but bearish for the AI companies themselves.
This kind of naive, out-of-the-box investment chases large effect size outcomes and could hit upon exciting cures. However, this operates on a time scale of decades with little chance of recouping massive hardware capex and high engineering salaries.
Related event: AI Companies' Pivot to Biomedical Research Raises Commercial Concerns(2 posts)→
More from AGI Musings
- The Essence of Tech Learning: Understanding Tradeoffs Outlasts Memorizing Facts — Franc0Fernand0 · 2026-07-30
- Altman Admits AI Job Apocalypse Hasn't Happened: Humans Still Value Trust — taherdhanera · 2026-07-30
- Blogger Predicts Doom for Apple Without Frontier AI, Claims OpenAI Will Dominate Hardware — iruletheworldmo · 2026-07-30
- DeepMind's Andrew Trask: Scaling Laws Are Pushing AI From Monolithic Models to Protocols — iamtrask · 2026-07-30
- Karpathy: Everything Will Operate Through Terminal in the AI Era — eptwts · 2026-07-30
- Wayve CEO on Where Embodied AI Finds Long-Term Competitive Advantage — alexgkendall · 2026-07-30